Treatment with immune-checkpoint blocking monoclonal antibody (mAb) is demonstrating a significant efficacy in different tumor types. Here, we discuss the impact of this promising approach in malignant mesothelioma (MM), a still dreadful disease in which medical treatment has been set on platinum based chemotherapy for decades with unsatisfactory results.

Additional Metadata
Keywords CTLA-4, Immune-checkpoint, Immunotherapy, Mesothelioma, PD-1, PD-L1
Persistent URL dx.doi.org/10.1016/j.cytogfr.2017.07.003, hdl.handle.net/1765/108651
Journal Cytokine and Growth Factor Reviews
Citation
Calabrò, L. (Luana), Ceresoli, G.L. (Giovanni Luca), D'Incecco, A. (Armida), Scherpereel, A, Aerts, J.G.J.V, & di Maio, R. (2017). Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences. Cytokine and Growth Factor Reviews, 36, 25–31. doi:10.1016/j.cytogfr.2017.07.003